Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development.

TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front and $4 million on

Read the full 393 word article

How to gain access

Continue reading with a
two-week free trial.